MEDVi vs Zealthy: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

MEDVi beats Zealthy overall, scoring 7.7/10 vs 7.2/10. MEDVi is more affordable at $179/mo vs $286/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Zealthy for insured users who want dedicated coordinators handling prior.

A side-by-side look at MEDVi and Zealthy to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Higher Rated

MEDVi

#20 of 52

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Zealthy

#41 of 52

7.2/10

Flexible GLP-1 provider allowing patients to switch between compounded and brand-name medications as needed.

Visit Zealthy

Feature	MEDVi	Zealthy
Our Score	7.7/10	7.2/10
Starting Price	$179/mo	$286/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Users who want a low entry price with oral and injectable compounded options	Insured users who want dedicated coordinators handling prior authorizations for brand-name GLP-1s (potentially $25/mo)
Ranking	#20	#41
Get started	Visit MEDVi	Visit Zealthy

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Zealthy

Pros

+Dedicated insurance coordinators handle prior authorizations, potentially bringing brand-name GLP-1 costs to $25/mo
+Multi-month supply options (3, 6, or 12 months), unique convenience most monthly-shipping competitors can't match
+Both compounded and brand-name (Wegovy, Zepbound) available with clinician-guided selection
+LegitScript certified with 4.5-star Review.io rating

Cons

−The $135 membership stacks on medication cost, so cash-pay semaglutide totals ~$286/mo, above average. The math works when you use the insurance coordination; cash payers should compare flat-rate platforms first.
−Young company (founded 2023) with a relatively small review base and less track record than established platforms. Confirm the coordination promise against your own insurance plan before enrolling.
−Prescription products are non-refundable once ordered, for any reason. Double-check dose and supply length before checkout.

Our Verdict

MEDVi edges out Zealthy with a score of 7.7/10 vs 7.2/10. If budget is your priority, MEDVi starts at $179/mo compared to Zealthy's $286/mo. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Zealthy if you want: insured users who want dedicated coordinators handling prior authorizations for brand-name glp-1s (potentially $25/mo).

Still undecided? Editor's Featured Pick

Yucca Health

$146/mo · 7.7/10 · Compounded

If neither MEDVi nor Zealthy feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.

Visit Yucca Health→Read our full Yucca Health review